Daiwa Securities Group Inc. Invests $82,000 in Haemonetics Co. (NYSE:HAE)

Daiwa Securities Group Inc. purchased a new position in Haemonetics Co. (NYSE:HAE) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,000 shares of the medical instruments supplier’s stock, valued at approximately $82,000.

Several other large investors have also recently modified their holdings of HAE. TFO Wealth Partners LLC raised its position in shares of Haemonetics by 29,450.0% in the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares during the last quarter. Covestor Ltd increased its holdings in Haemonetics by 184.8% in the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Haemonetics in the 1st quarter worth about $86,000. Headlands Technologies LLC bought a new stake in Haemonetics in the 1st quarter worth about $114,000. Finally, Central Pacific Bank Trust Division bought a new stake in Haemonetics in the 1st quarter worth about $139,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 0.2 %

Shares of NYSE:HAE opened at $76.57 on Wednesday. The stock has a 50 day moving average of $81.05 and a 200 day moving average of $84.07. The company has a market cap of $3.90 billion, a PE ratio of 33.44, a price-to-earnings-growth ratio of 1.32 and a beta of 0.30. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The company had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The company’s revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.05 earnings per share. As a group, equities research analysts expect that Haemonetics Co. will post 4.58 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on HAE shares. CL King started coverage on Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective for the company. Needham & Company LLC upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Wednesday, June 12th. Bank of America began coverage on Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. BTIG Research began coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target for the company. Finally, Citigroup cut their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $106.14.

Insider Buying and Selling

In related news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Anila Lingamneni sold 2,136 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the transaction, the executive vice president now directly owns 21,410 shares in the company, valued at $1,926,900. The disclosure for this sale can be found here. 1.80% of the stock is owned by insiders.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.